- Home
- DIAX vs FULC Comparison
DIAX vs FULC Comparison
Compare DIAX & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DIAX | FULC |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 553.9M | 468.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | DIAX | FULC |
|---|---|---|
| Price | $15.51 | $10.13 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.38 |
| AVG Volume (30 Days) | 96.6K | ★ 1.4M |
| Earning Date | 01-01-0001 | 02-24-2026 |
| Dividend Yield | ★ 7.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2752.05 |
| 52 Week Low | $12.80 | $2.32 |
| 52 Week High | $15.12 | $15.74 |
Technical Indicators
Market Signals| Indicator | DIAX | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 66.53 | 41.73 |
| Support Level | $15.10 | $9.77 |
| Resistance Level | $15.38 | $12.27 |
| Average True Range (ATR) | 0.18 | 0.70 |
| MACD | 0.03 | -0.34 |
| Stochastic Oscillator | 84.81 | 12.14 |
Price Performance
Historical ComparisonAbout DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.